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CC BY-NC-ND license (http://creativeAbstract Objective: To establish a rat model of type 2 diabetes (T2DM) manifesting the Chi-
nese medicine syndrome pattern of both qi and yin deficiency for evaluating the efficacy of a
Chinese herbal formula (CHF), integrative medicine (IM), and pioglitazone (PIO) on T2DM indi-
cators in the animal model.
Methods: The rat model was induced by a high-fat diet (HFD) and streptozotocin (STZ, 30 mg/
kg). CHF (3.4 g/kg), PIO (2.7 mg/kg), and IM (3.4 g CHF þ 2.7 mg PIO) were administered to rats
once daily for 14 days. Related laboratory parameters were observed.
Results: Diabetic rats showed unsmooth fur, alopecia, reduced activity, huddling, somnolence,
depression, pale or reddened tongue, damp/dark red tail, and high levels of water and food
intake, urine volume, and stool weight, but weakened grip strength. Low levels of serum
SOD, Naþ-Kþ-ATPase, cAMP/cGMP, and a high level of iNOS were observed. Hyperglycemia, hy-
perinsulinemia, insulin resistance, high levels of serum glucagon/IDE and pancreatic amylin,
and low serum and pancreatic SS levels were evident as well.
Conclusions: A rat model of T2DM with both qi and yin deficiency was successfully replicated.
CHF appeared to be more efficacious than IM and PIO in the rat model of qi and yin deficiency
pattern of T2DM, though IM and PIO were each found to have their merits and drawbacks in
attenuating T2DM indicators in the rat model.
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Table 1 Composition of Chinese herbal formula (CHF).
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part
Amount used
(%)
Astragalus
Astragalus membranaceus
(Fisch.) Bunge
Root 25.4
Cooked rehmannia
Rehmannia glutinosa
(Gaertn.) DC.
Root 20.3
Dioscorea
Dioscorea oppositifolia L.
Root 20.3
Cornus
Cornus officinalis Sieb.et Zucc.
Fruit 16.9
Ophiopogon
Ophiopogon japonicas (Thunb.)
Ker Gawl.
Tuber 16.9Integrative medicine (IM) is defined as the combination of
traditional Chinese medicine (TCM) and western medicine
(WM). In China, TCM, WM, and IM are all treatment methods
in the clinics. IM is especially popular in China and Asia in
general.1e3 It is thought that IM’s advantage is that it is
efficacious with few side effects.4 A large number of clin-
ical pharmacology studies on IM, most of which give priority
to WM and few to TCM, have been reported and the main
evaluation system is based on indicators of WM.5e8 To date,
there has been no systematic evaluation that includes both
disease indicators of WM and syndrome patterns of TCM.
Given that TCM and WM have their own merits and
characteristics,9,10 there are many explanations for the
curative effects of IM, such as a synergistic effect, an
antagonistic effect, and no significant effect but to miti-
gate side-effects. Moreover, research is limited by many
factors that make it impossible for IM to be studied in a
clinical environment. It is also impossible to prohibit IM in
unconfirmed clinical research. Therefore, establishing an
experimental IM design that uses a pharmacologic evalua-
tion is important for guidance of medication safety.
Type 2 diabetes (T2DM), formerly called non-insulin-
dependent diabetes mellitus and commonly caused by in-
sulin resistance, accounts for about 90% of diabetes.11 In
TCM theory, T2DM is known as wasting and thirsting disor-
der, and the disease progresses in a set way.12,13 In the
early stages, yin deficiency or deficiency of both qi and yin
is the main pattern. In subsequent stages, the pattern turns
into one of stasis of phlegm and blood.
Liu et al. established a rat T2DM model of the TCM
pattern of deficiency of both qi and yin with a high-fat diet
and low dose streptozocin.13 In our study, we replicated
this animal model. Subsequently, a system of laboratory
indicators based on disease indicators of T2DM and a TCM
pattern of deficiency of both qi and yin was established. A
Chinese herbal formula (CHF) was then used to validate the
rat model and assess its efficacy in treating T2DM in rats.
The CHF was based on an extensive literature search for
effective traditional medicinal used empirically to treat
T2DM and on the TCM treatment strategy of reinforcing qi
and replenishing yin. Pioglitazone hydrochloride (PIO), a
widely-prescribed agent for T2DM,14 was used as the WM
control. CHF and PIO comprised the IM. We also evaluated
the efficacies of IM, CHF, and PIO.
Materials and methods
Preparation of CHF
CHF was composed of five herbal medicines (Table 1). The
raw herbs were purchased from Beijing Tong Ren Tang
Herbal Pharmacy (Beijing, China) and authenticated by
Professor Chunsheng Liu at Beijing University of Chinese
Medicine. For the preparation of the aqueous extract of
CHF, all herbs except dioscorea rhizome (Dioscorea oppo-
sitifolia L.) were soaked in 8 volumes of water for 2 h, and
decocted (extracted) three times for 1 h each. The pooled
aqueous extract was filtered through gauze and concen-
trated and dried under vacuum at 70C. The extraction ratewas 65.76%; soft material was made by adding dioscorea
rhizome (Dioscorea oppositifolia L.) flour and 95% ethanol,
then dried at 70C and pelletized by micro-mesh sieve
(1.58 g of herbs for every 1 g of granule).
Chemicals and reagents
Pioglitazone hydrochloride (PIO) was purchased from
Takeda Pharmaceutical (Tianjin, China); streptozotocin
(STZ) was purchased from Sigma-Aldrich (St. Louis, MO,
USA); sodium citrate and citric acid were purchased from
West Long-Chemical (Guangdong, China); 0.01 M PBS
(pHZ 7.4e7.6) was purchased from Fuzhou Maixin Biotech
(Fuzhou, China); blood glucose test strips were purchased
from Johnson and Johnson Medical (Shanghai, China);
diethyl ether was purchased from Beijing Chemical Factory
(Beijing, China); vacuum blood collection tubes were
Hunan Liuyang Medical Instruments (Liuyang, Hunan,
China). Assay kits and reagents were purchased from
RGB&CHN (Beijing, China).
Animals
Male Sprague-Dawley (SD) rats (specific pathogen free),
weighing 180e200 g, were purchased from the Vital River
Laboratory (Beijing, China). Rats were housed in the animal
center of Beijing University of Chinese Medicine under
standard conditions at 21e23C, with a relative humidity of
50e60%. High-fat diet (HFD) consisting of 75% basal diet,
10% lard, 5% sugar, 5% egg yolk powder, 2% cholesterol, and
0.5% ox-gall acid sodium, were provided by the Beijing
branch of Australia Together to Feed Co, Ltd (Beijing,
China).
All experimental procedures were approved by the Uni-
versity Committee on Research Practice, Beijing University
of Chinese Medicine.
Establishing rat model of T2DM
The rat model of T2DM was established as described by
Mansor, et al.15 Briefly, after adaptive breeding for 5 days, 65
rats were assigned randomly and divided into 2 groups:
260 J. Zhao et al.normal group (nZ 10) and model group (nZ 55). From the
first day of the experiment, animals in the normal groupwere
given basal feed, while rats in themodel groupwere fedwith
HFD for 5 weeks. Afterward, the model group rats were
treated with STZ (30 mg/kg, dissolved in 0.1 mol/L citrate
buffer, pH Z 4.3, i.p.). The normal group received only a
vehicle buffer injection. Diabetes was verified 72 h later by
evaluating blood glucose levels with the use of blood glucose
test strips. Diabetes was induced successfully when the
fasting blood glucose (FBG) level of rats was higher than
11.1 mmol/L. Of these rats, 75% developed T2DM and were
maintained on HFD for an additional 2 weeks.
Experiment design
Design one
Ten rats were randomly selected from the normal group
(NG) or the diabetes group (DG) on day 53 of the experi-
ments. The grip strength data, as averaged values, were
measured thrice using YLS-13A grip strength meter. Food-
intake, water-intake, urine volume, and stool weight were
measured for 24 h. Rats’ behavior was recorded (Table 2).16
At the end of the trial, after 12 h of food deprivation, blood
samples were taken from the tail vein for measuring FBG
level. Rats were sacrificed under light ether anesthesia and
blood samples were collected from the aorta ventralis.
Serum samples were prepared by centrifuging 2000 g whole
blood for 15 min and stored at 80C until used for
biochemical analysis. Pancreas tissue samples were ob-
tained and stored at 80C until used for biochemical
analysis.
Design two
This study investigated the effect of drug intervention on
the above mentioned indicators (Table 2). Thirty rats were
randomly selected from DG on day 38, and then divided into
the PIO group, CHF group, and IM group. Ten rats were
assigned to each treatment group. Rats in the PIO group
were treated with pioglitazone hydrochloride for 14 days by
oral administration (2.7 mg/kg), rats in the CHF group were
treated with CHF (3.4 g/kg, the human equivalent dose) for
14 days, while rats in the IM group were treated with CHF
(3.4 g/kg) and pioglitazone hydrochloride (2.7 mg/kg) for
14 days. On Day 53, rats were treated according to the
above mentioned methods.
Biochemical analysis
The index of a homeostasis model assessment of insulin
resistance (HOMA-IR) was calculated as follows: FBGTable 2 Standard for evaluation of rat behavior.
Indicators Description and standard for evaluation (scores)
Fur Alopecia and greasy (3) Alopecia (2)
Tongue
texture
Ecchymosis (3) Reddened tongue (2)
Tail Ecchymosis (3) Damp or dark red (2)
Behavior Huddling (2) Decreased activity (1)
Emotion Dispirited (2) Somnolent (1)(mmol/L)  Fins (m U/L)/22.5. The insulin sensitive index
(ISI) was calculated as 1/[FBG (mmol/L)  Fins (m U/L)].
The levels of cAMP, cGMP, Fins, glucagon, IDE, SS, and
amylin were analyzed by the ELISA method and iNOS, SOD,
Naþ-Kþ-ATPase were analyzed by automatic biochemistry
analyzer according to kit procedures.
Statistical analysis
Results were presented as mean (SE). Data between mul-
tiple groups were analyzed by one-way analysis of variance
(ANOVA) using SPSS version 20.0 (IBM, Armonk, NY, USA),
and differences among means were analyzed using Dun-
nett’s multiple comparisons test or post hoc analysis. Dif-
ferences were considered significant at P < .05.
Results
The effects of IM on fur, behavior, emotion, tongue texture,
tail appearance, food-intake, water-intake, urine volume,
stool weight, body weight, and grip strength were
observed. Table 3 shows that the changes in fur, behavior,
emotion, tongue texture, and tail appearance were signif-
icant in DG when compared with NG (P < .001). After 14
days of CHF, IM and PIO treatment in diabetic rats, changes
in fur (P < .001), behavior (P < .001, P < .001, P < .01,
respectively), and emotion (P < .001, P < .01, P < .05,
respectively) were all significant, when compared with the
DG. Moreover, in the CHF and IM groups, changes in tongue
texture (P < .01, P < .05, respectively) and tail appearance
(P < .001, P < .01, respectively) were significant, but
changes in tongue texture (P > .05) and tail appearance
(P > .05) were not significant in the PIO group.
Table 3 also shows that the water intake, urine volume,
food intake, and stool weight were significantly increased
in DG when compared with NG (P < .001). After 14 days of
CHF, IM and PIO treatment in diabetic rats, the water
intake (P < .01, P < .001, P < .001, respectively) increased
noticeably, when compared with the DG. However, the
changes in urine volume, food intake, and stool weight
were not significant (P > .05). Additionally, the changes in
body weight and grip strength were not significant in the DG
when compared with the NG (P > .05). After 14 days of CHF,
IM, and PIO treatment, grip strength decreased noticeably
when compared with the DG (P < .001), but change in body
weight was not significant (P > .05).
With respect to the effects of IM on serum SOD, cAMP/
cGMP, iNOS, Naþ-Kþ-ATPase levels, Table 4 shows that SOD
and Naþ-Kþ-ATPase decreased significantly whereas the
level of iNOS increased significantly in the DG whenUnsmooth and dull (1) Smooth (0)
Pale tongue (1) Normal (0)
Red (1) Normal (0)
Moderate activity (0) Highly active (1) Excited (2)
Normal (0) Excited (1) Agitated (2)
Table 3 Effects of IM on fur, behavior, emotion, tongue texture, tail appearance, food-intake, water-intake, urine volume,
stool weight, body weight, and grip strength.a
Indicators n NG DG CHF IM PIO F Value
Fur (score) 10 0.00  0.00 1.20  0.13** 0.30  0.15## 0.30  0.15## 0.40  0.16## 11.14
Behavior (score) 10 0.00  0.00 1.70  0.15** 0.60  0.16## 0.50  0.17## 0.90  0.23## 14.86
Emotion (score) 10 0.10  0.10 1.40  0.22** 0.40  0.22## 0.50  0.17## 0.80  0.20# 8.69
Tongue texture
(score)
10 0.00  0.00 1.30  0.21** 0.50  0.17## 0.70  0.21# 0.90  0.23 6.69
Tail (score) 10 0.00  0.00 1.90  0.18** 1.00  0.21## 1.10  0.10## 1.50  0.22 18.48
Food-intake (g) 10 22.43  1.32 33.95  0.55** 33.08  0.87 32.45  0.55 34.45  0.33 39.13
Water-intake (mL) 10 128.13  1.23 190.25  1.42** 203.75  4.80## 238.00  3.92## 251.50  1.97## 254.73
Urine volume (mL) 10 10.95  1.29 36.13  1.95** 32.63  1.79 32.18  1.12 35.56  1.70 43.13
Stool weight (g) 10 6.54  0.43 20.14  1.98** 18.59  0.50 18.38  0.46 20.31  0.31 36.06
Body weight (g) 10 460.25  9.04 444.71  7.31 449.05  12.99 463.04  10.53 444.35  8.86 0.785
Grip strength (N) 10 1702.56  64.28 1691.69  61.18 1277.29  85.54## 1202.29  52.39## 1291.69  42.63## 15.00
Abbreviations: CHF, Chinese herbal formula; DG, diabetes group; IM, integrated medicine; NG, normal group; PIO, pioglitazone.
*P < .05, **P < .01 versus NG; #P < .05, ##P < .01 versus DG. Statistically significant differences were determined using a one-way ANOVA
followed by Dunnett’s multiple comparisons test or post hoc analysis.
a Values are expressed as mean (SE), with n Z 10.
Efficacy of integrative medicine in deficiency 261compared with the NG (P < .001). After 14 days of CHF, IM
and PIO treatment in diabetic rats, the level of SOD
increased significantly when compared with the DG
(P < .001). In addition, the levels of iNOS decreased
significantly in the CHF and IM groups (P < .001), but the
change of iNOS level was not significant in the PIO group
(P > .05) when compared with the DG. In addition, the level
of Naþ-Kþ-ATPase significantly increased in the CHF group
(P < .05), but the changes of Naþ-Kþ-ATPase levels were
not significant in the IM and PIO groups (P > .05) when
compared with the DG.
Table 4 also shows that the cAMP/cGMP level signifi-
cantly decreased in the DG when compared with the NG
(P < .001). After 14 days of CHF, IM and PIO treatment in
diabetic rats, the level of cAMP/cGMP significantly
increased in the CHF group (P < .001), but the changes of
cAMP/cGMP levels were not significant in the IM and PIO
groups (P > .05) when compared with the DG.
The effects of IM on FBG, serum Fins, HOMA-IR, ISI, and
serum glucagon/IDE/SS levels, as well as pancreatic amylin
and SS levels are shown in Table 5. It shows that the levels
of FBG, Fins and HOMA-IR significantly increased, but the
level of ISI significantly decreased in the DG when
compared with the NG (P < .001). After 14 days of CHF, IM,
and PIO treatment in diabetic rats, the levels of FBGTable 4 Effects of IM on serum SOD, cAMP/cGMP, iNOS, Naþ-Kþ
Indicators N NG DG CHF
SOD (U/mL) 10 146.36  0.67 65.69  5.50** 143.
iNOS (U/mL) 10 13.44  0.86 46.75  5.32** 17.
Naþ-Kþ-ATPase
(U/mL)
10 11.33  1.90 3.68  0.58** 6.
cAMP/cGMP 10 0.46  0.03 0.13  0.01** 0.
Abbreviations: CHF, Chinese herbal formula; DG, diabetes group; IM,
*P < .05, **P < .01 versus NG; #P < .05, ##P < .01 versus DG. Statisticall
followed by Dunnett’s multiple comparisons test or post hoc analysis
a Values are expressed as mean (SE), with n Z 10.(P < .001, P < .01, P < .05) and HOMA-IR (P < .001, P < .05,
P < .05) decreased noticeably, respectively, when
compared with DG. Moreover, the level of Fins significantly
decreased in the CHF group (P < .01), but the changes of
Fins levels were not significant in the IM and PIO groups
(P > .05) when compared with the DG. In addition, the level
of ISI significantly increased in the CHF group (P < .01), but
the changes of ISI levels were not significant in the IM and
PIO groups (P > .05) when compared with the DG.
Table 5 also shows that the glucagon and serum IDE
levels significantly increased (P < .001) but the level of
serum SS (P < .01) significantly decreased in the DG, when
compared with the NG. After 14 days of CHF, IM and PIO
treatment in diabetic rats, the levels of glucagon were
significantly decreased in the CHF and PIO groups (P < .01),
whereas the change in glucagon level was not significant in
the IM group (P > .05) when compared with the DG. In
addition, the level of serum SS significantly increased in
the PIO group (P < .05), but the changes of serum SS levels
were not significant in the CHF and IM groups (P > .05)
when compared with the DG. In addition, the levels of
serum IDE significantly decreased in the CHF (P < .01) and
IM (P < .05) groups, but the change of serum IDE level was
not significant in the PIO group (P > .05) when compared
with the DG.-ATPase levels.a
IM PIO F value
61  1.05## 140.86  1.77## 140.43  1.35## 185.77
37  1.38## 20.52  2.46## 44.16  6.04 16.65
70  1.01# 6.06  0.67 4.31  0.87 7.59
30  0.02## 0.15  0.01 0.16  0.01 71.44
integrated medicine; NG, normal group; PIO, pioglitazone.
y significant differences were determined using a one-way ANOVA
.
Table 5 Effects of IM on FBG, serum Fins, HOMA-IR, ISI, and serum glucagon/IDE/SS levels, as well as pancreatic amylin and SS
levels.a
Indicators N NG DG CHF IM PIO F value
FBG (mmol/L) 10 5.06  0.24 23.48  0.71** 19.34  0.42## 21.05  0.54# 21.68  0.76 172.34
Fins (mU/L) 10 11.70  0.47 15.85  1.09** 12.97  0.51## 14.97  0.38 14.24  0.56 6.31
HOMA-IR (mmol$mU/L2) 10 2.60  0.10 16.45  1.06** 11.13  0.43## 13.99  0.48## 13.64  0.50## 79.95
ISI  103 (mmol$mU/L2)1 10 17.29  0.63 2.80  0.18** 4.05  0.15## 3.21  0.11 3.30  0.13 414.10
Serum glucagon (ng/L) 10 98.81  3.51 131.78  5.33** 115.45  1.80## 122.21  2.95 114.00  4.10## 10.56
Serum SS (ng/L) 10 24.67  2.35 18.53  0.96** 18.74  0.56 20.25  0.96 23.66  1.30# 4.23
Serum IDE (mg/L) 10 7.24  0.25 9.43  0.78** 7.56  0.25## 8.17  0.28# 9.09  0.36 5.50
Pancreatic amylin (ng/g) 10 2.72  0.21 13.42  1.66** 8.19  0.78## 4.82  0.69## 2.95  0.41## 26.36
Pancreatic SS (ng/g) 10 6.05  0.77 3.21  0.29** 5.57  0.58## 4.37  0.63 3.18  0.14 6.30
Abbreviations: CHF, Chinese herbal formula; DG, diabetes group; IM, integrated medicine; NG, normal group; PIO, pioglitazone.
*P < .05, **P < .01 versus NG; #P < .05, ##P < .01 versus DG. Statistical significant differences were determined using a one-way ANOVA
followed by Dunnett’s multiple comparisons test or post hoc analysis.
a Values are expressed as mean (SE), with n Z 10.
262 J. Zhao et al.In addition, Table 5 shows that the level of pancreatic
amylin significantly increased but the level of pancreatic SS
significantly decreased in the DG when compared with NG
(P < .001). After 14 days of CHF, IM and PIO treatment in
diabetic rats, the levels of pancreatic amylin decreased
noticeably when compared with the DG (P < .001). The
level of pancreatic SS significantly increased in the CHF
group (P < .01), but the changes of pancreatic SS levels
were not significant in the IM and PIO groups (P > .05) when
compared with the DG.
Discussion
IM as the main type of treatment in clinics is popular in
Asia, especially in China,1 and a large number of studies
relating to the evaluation of the curative effect have been
reported.5e8 However, evaluation systems are mainly based
on the efficacy of the treatment of diseases and are rarely
based on the efficacy of the treatment of the syndrome.6,7
In the modern pharmacodynamics study of IM, there is a
shortage of balance in the system of evaluation combining
disease with syndrome.
T2DM is a chronic metabolic disease that has a high
blood glucose level and affects the body’s ability to turn
food into energy.17 The basic characteristic of T2DM is in-
sulin resistance and T2DM can lead to serious complications
that decrease quality of life.18e20 Anti-diabetic drugs are
commonly used to manage diabetes and there are a number
of different types of them including biguanides, sulfonyl-
urea, thiazolidinediones, benzoic acid derivatives, a-
glucosidase inhibitors, dipeptidyl peptidase-4 inhibitor, and
glucagon-like peptide 1. Pioglitazone hydrochloride as a
representative drug of thiazolidinediones is widely used in
the treatment of T2DM.14 Therefore, we chose pioglitazone
as the western medicine control. In terms of traditional
Chinese medicine, a deficiency of both qi and yin is the
basic syndrome pattern during the whole process of
T2DM,13 and its main clinical manifestations are poly-
phagia, polyuria, polydipsia, loss of weight, disinclination
to talk due to lack of qi, fatigue and lassitude, thready and
rapid pulse, etc. We prescribed CHF consisting of Chinese
medicinal herbs reinforcing qi and replenishing yin. SinceCHF has a therapeutic effect on T2DM,13 it was used as the
traditional Chinese medicine control.
In addition, it has been reported and confirmed that the
activities levels of SOD, iNOS, Naþ-Kþ-ATPase, cAMP, and
cGMP have a close relationship with the deficiency of both
qi and yin syndrome.5,21 In this study, HFD and 30 mg/kg
STZ were used to replicate disease-syndrome in our rats’
model of T2DM. Unsmooth fur, alopecia, decreased activity,
huddling, somnolence, depression, pale or reddened
tongue, and dampness/dark red tail were found in diabetic
rats. Moreover, high levels of water intake, food intake,
urine volume, and stool weight, but low level of grip
strength were found in diabetic rats. In addition, low levels
of serum SOD, Naþ-Kþ-ATPase, cAMP/cGMP, and high level
of iNOS were found in diabetic rats. In conclusion, a rats’
model of the deficiency of both qi and yin syndrome was
successfully replicated.
Hyperglycemia, hyperinsulinemia, and insulin resistance
are the basic characteristics of T2DM.17,22,23 Glucagon and
insulin, which are secreted from the a and b cells of
pancreatic islets, are the primary blood glucose regulating
hormones and have antagonistic action.24 IDE is a 110 kDa
and closely associated with T2DM by degrading insulin and
amylin.25 Moreover, it is confirmed that IDE is identified as a
candidate susceptibility gene of T2DM in rats.26 Amylin is a
pancreatic b cell glucoregulatory hormone, and it is also a
vital regulator of energy metabolism.27 In addition, a pre-
vious study showed that amylin is a risk factor of hyper-
insulinemia.28 Somatostatin secreted in various parts of
body, including the pancreatic d cell, inhibits glucagon and
insulin secretions by paracrine.29 In this study, we found
hyperglycemia, hyperinsulinemia, insulin resistance, and
high levels of serum glucagon/IDE and pancreatic amylin, as
well as low serum and pancreatic SS levels. Those results
showed that a T2DM rat’s model along with hormonal
disturbance was successfully replicated.
From our results, it was found that the efficacy of CHF
was superior to IM, and IM was superior to PIO in targeting
deficiency of both qi and yin syndrome pattern. Moreover,
efficacy of CHF was found to be superior to PIO, and PIO
was superior to IM in attenuating T2DM indicators. The
Chinese herbal formula we evaluated appeared to be
Efficacy of integrative medicine in deficiency 263efficacious, though IM and PIO had their own merits and
drawbacks. These results reinforce the concept that IM
does not have an absolute advantage for all syndrome
patterns and diseases and that clinicians should focus on
individualized drug administration.
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